|Status : Published||Published On : May, 2021||Report Code : VRHC1199||Industry : Healthcare||Available Format :||Page : 96|
The U.S. drug of abuse (DoA) testing market is expected to grow at a CAGR of 9.7% during the forecast period with its market size predicted to reach USD 4.6 billion by 2027. The U.S. DoA testing market is primarily driven by the stringent laws and regulations, government initiatives, and increasing awareness against drug abuse and development of advanced drug test equipment. The testing for drug abuse requires products such as immunoassay analyzers, chromatography instruments, breath analyzers, rapid test kits, and assay kits & reagents.
Insight by Product
Among the various products being used for testing drug abuse, the rapid test kits account for the largest demand in the U.S. DoA testing industry. The high demand for these kits is primarily due to the need for easily available and accessible testing for on the spot drug abuse testing. The rapid test kits as per its name also present output in a short time thereby has higher demand in comparison to the other product category. The market for breath analyzers is expected to grow at the highest CAGR during the forecast period.
Insight by Sample Type
The DOA tests make use of human samples such as urine, saliva, hair, blood, breath, and others. Urine is majorly used for drug abuse testing since it contains parent drugs or metabolites in them, that is tested for the presence of major illicit drugs. The urine samples lead the global DOA testing market based on size. Some of the other sample type used includes tissue and sweat.
Insight by End User
Hospitals are the largest end user for the DoA products and are also estimated to retain the largest market size during the forecast period. The category’s large size is due to the increasing number of research and drug test being conducted. The hospitals account to hold high number of tests due to the availability of products on a large scale as compared to other end users of DOA testing. Also, the presence of number of clinicians in hospitals is larger, marking its large share over others.
The stringent laws and regulations, government initiatives to curb drug abuse, and increasing awareness against drug abuse and development of advanced drug test equipment are the primary growth drivers for the U.S. DoA testing industry. The substance misuse and its addiction of opioids such as morphine and heroin have been a serious concern for the U.S. government as it affects the socio-economic welfare and public healthcare. The National Institute on Drug Abuse reported that an estimated 1.9 million people in the United States suffered from substance use disorders related to prescription opioid pain medicines in 2013 and 517,000 suffered from a heroin use disorder.
The government in the country is promoting educational initiatives to be delivered in school and communities, supporting prescription drug monitoring programs, implementing overdose education and naloxone distribution programs, and aggressive law enforcement efforts. The government is also supporting the investment for research and development for pain management and next-generation analgesics. This is anticipated fuel the market for DoA testing in the U.S.
The legalization of certain drugs and inability to detect low dose modified drugs are the key challenges faced by the U.S. DoA testing industry.
Some of the key players operating in the U.S. DoA testing market are Siemens AG, Danaher Corporation, Merck KGaA, Laboratory Corporation of America Holdings, Express Diagnostics Int'l, Inc., Quest Diagnostics Inc., Waters Corporation, Abbott Laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche AG.
PRIMARY RESEARCH INTERVIEWS - BREAKDOWN